重组人红细胞生成素治疗化疗相关性贫血的疗效观察

Clinical observation of erythropoietin in treating the cancer-reated anemia after chemotherapy

目的评价重组人红细胞生成素(Recombinant Human Erythropoietin Injection,rHuE-PO)治疗肿瘤化疗相关性贫血的疗效和安全性。方法化疗相关性贫血的患者36例,其中21例行rHuEPO治疗,用法为:150 u/kg.次,皮下注射3次/周,疗程4-8周,同时给予中药及支持治疗。15例未用rHuEPO治疗。所有36例患者若出现严重贫血则给予输血治疗,以保证化疗继续进行。观察rHuEPO对血红蛋白(Hb)、红细胞比容(Hct)等的影响,以及对患者生活质量的影响和副反应。结果治疗组治疗后Hb水平显著提高,4周有效率66.7%,对照组无明显提高;治疗组治疗后两周内网织红细胞计数显著提高,对照组治疗前后无变化。应用rHuEPO无严重副反应发生,安全性高,患者生活质量有所改善。结论rHuEPO治疗肿瘤化疗相关性贫血的疗效肯定。rhuEPO不仅有效提高Hb水平,而且安全性高,副反应少,能够改善患者生存质量。

Objective To observe the effect of recombinant human erythropietin （rHuEPO） in treating cancer-related anemia after chemotherapy. Methods Twenty one case of treated group were trea- ted with rHuEPO 100 U/kg, qod, lasted for 4 - 8 weeks. If all 36 sufferers appear the severe anemic then give the blood transfusion treatment. Twenty one cases of control group were treated with support cares. Observe the influence of the rHuEPO to the Hct, Hb, and to life quantity of the sufferer. Results The overall response rates of treated and control group were 66.7% and 13.3% respectively, and the increased Hb of treated group is more higher than that of control group （ P 〈 0. 05 ）. Conclusion rHuEPO is effective and safe in treating the cancer-related anemia, rhuEPO has the high safety, little characteristics of vice-reaction, can improve the sufferer＇s existence quantity.